Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Explore this paper's citation graph
Summary
Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo.
- Type
- article
- Published
- 2019-11-16
- Cited by
- 2,370
- References
- 20
- Access
- Open access
- OpenAlex
- https://openalex.org/W2986700515
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:261067401
Keywords
Colchicine, Gout, Medicine, Pericarditis, Myocardial infarction
References
- Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event.
- Analysing recurrent hospitalisations in heart failure: a review of statistical methodology, with application to CHARM-Preserved
- Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation.
- Methods for analysis of multiple events in the presence of death.
- Comparison of the Andersen-Gill model with poisson and negative binomial regression on recurrent event data
- The importance of varying the event generation process in simulation studies of statistical methods for recurrent events
- Semiparametric regression for the mean and rate functions of recurrent events
- Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update.
- The role of interleukin-1 and the inflammasome in gout: implications for therapy.
- A Proportional Hazards Model for the Subdistribution of a Competing Risk
- Colchicine intoxication and infection risk: a case report
- Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study"
- Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
- An overview of statistical methods for multiple failure time data in clinical trials.
- Colchicine in Addition to Conventional Therapy for Acute Pericarditis: Results of the COlchicine for acute PEricarditis (COPE) Trial
- Low-dose colchicine for secondary prevention of cardiovascular disease.
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
- Inflammation, Atherosclerosis and Coronary Artery Disease
Cited by
- Lo mejor del 2020: estudios que marcarán nuestra práctica clínica
- Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021
- Myeloid But Not Endothelial Expression of the CB2 Receptor Promotes Atherogenesis in the Context of Elevated Levels of the Endocannabinoid 2-Arachidonoylglycerol
- Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology.
- Anti-inflammatory therapy for secondary prevention after MI
- COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events.
- Colchicin reduziert ischämische Komplikationen nach Herzinfarkt
- Balancing progress and practice: Preventive cardiology in the 2020s.
- The year in cardiology: cardiovascular prevention.
- Pleiotropic effects of statins on ischemic heart disease: a Mendelian Randomization study in the UK Biobank
- Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions
- Familial Mediterranean fever is associated with increased risk for ischaemic heart disease and mortality–Perspective derived from a large database
- Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
- Reappraising the role of inflammation in heart failure
- Metabolic Regulators of Vascular Inflammation.
- Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective
- Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.
- Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease.
- 60 years of clonal hematopoiesis research: from X-Chromosome Inactivation studies to the identification of driver mutations.
- Peri-coronary inflammation is associated with findings on coronary computed tomography angiography and fractional flow reserve.
Related papers
- Management of gout.
- Treatment of gout.
- Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients.
- Colchicine reduces incidence of atrial arrhythmias in rabbit sterile pericarditis models through anti-inflammatory and reducing expression of kir3.4 mRNA
- Pharmacotherapy: Colchicine for recurrent pericarditis—what's new in CORP-2?
- Colchicine for pericarditis.
- [Recurrent pericarditis: our experience with colchicine].
- Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis.
- A case of recurrent benign pericarditis treated by colchicine.